Skip to main content

What the label lists and what reports show

Clofarabine side effects

Clofarabine's FDA label: “Most common adverse reactions (≥25%): vomiting, nausea, diarrhea, febrile neutropenia, pruritus, headache, bacteremia, pyrexia, rash, tachycardia, abdominal pain, chills, fatigue, anorexia, pain in extremity, hypotension, epistaxis, and petechiae.” FAERS holds 2,271 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is febrile neutropenia (270 reports).

  • Generic listed

Check it at the source: the clofarabine FDA label on DailyMed (effective December 12, 2022, Meitheal Pharmaceuticals Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

Most common adverse reactions (≥25%): vomiting, nausea, diarrhea, febrile neutropenia, pruritus, headache, bacteremia, pyrexia, rash, tachycardia, abdominal pain, chills, fatigue, anorexia, pain in extremity, hypotension, epistaxis, and petechiae.

Table 2: Incidence of Treatment-Emergent Laboratory Abnormalities after Clofarabine Administration

ParameterAny GradeGrade 3 or higher
Anemia (N=114)83%75%
Leukopenia (N=114)88%88%
Lymphopenia (N=113)82%82%
Neutropenia (N=113)64%64%
Thrombocytopenia (N=114)81%80%
Elevated Creatinine (N=115)50%8%
Elevated SGOT (N=100)74%36%
Elevated SGPT (N=113)81%43%
Elevated Total Bilirubin (N=114)45%13%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

The following clinically significant adverse reactions are discussed in greater detail in other sections of the label: Myelosuppression [see Warnings and Precautions ( 5.1 )] Hemorrhage [see Warnings and Precautions ( 5.2 )] Serious Infections [see Warnings and Precautions ( 5.3 )] Hyperuricemia (tumor lysis syndrome) [see Warnings and Precautions ( 5.4 )] Systemic Inflammatory Response Syndrome (SIRS) and Capillary Leak Syndrome [see Warnings and Precautions ( 5.5 )] Venous Occlusive Disease of the Liver [see Warnings and Precautions ( 5.6 )] Hepatotoxicity [see Warnings and Precautions ( 5.7 )] Renal Toxicity [see Warnings and Precautions ( 5.8 )] Enterocolitis [see Warnings and Precautions ( 5.9 )] Skin Reactions [see Warnings and Precautions ( 5.10 )] Most common adverse reactions (≥25%): vomiting, nausea, diarrhea, febrile neutropenia, pruritus, headache, bacteremia, pyrexia, rash, tachycardia, abdominal pain, chills, fatigue, anorexia, pain in extremity, hypotension, epistaxis, and petechiae. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Source: FDA drug label, Meitheal Pharmaceuticals Inc., effective December 12, 2022 (SPL set 54436453-882e-406b-87a3-049d150101c6), via openFDA; the full label on DailyMed

What do FAERS reports show?

2,271 reports list clofarabine among the medicines taken, each a report of something that happened, not proof the medicine caused it; 900 are coded as a death and 717 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 21 reactions below, 13 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Febrile Neutropenia (named in the label)270
  • Off Label Use (a use or a product term, not a reaction)239
  • Pyrexia (named in the label)207
  • Drug Ineffective (a use or a product term, not a reaction)196
  • Sepsis (named in the label)160
  • Mucosal Inflammation (named in the label)125
  • Neutropenia (named in the label)121
  • Nausea (named in the label)111
  • Death (an outcome recorded in the report)104
  • Vomiting (named in the label)101
  • Pancytopenia100
  • Blood Bilirubin Increased97
  • Product Use In Unapproved Indication (a use or a product term, not a reaction)97
  • Pneumonia (named in the label)92
  • Multiple Organ Dysfunction Syndrome89
  • Alanine Aminotransferase Increased86
  • Hypotension (named in the label)86
  • Bone Marrow Failure83
  • Aspartate Aminotransferase Increased81
  • Thrombocytopenia (named in the label)81
  • Oedema (named in the label)79
  • Respiratory Failure76
  • Septic Shock (named in the label)73
  • Acute Kidney Injury72
  • Diarrhoea (named in the label)72

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Clofarabine: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions